Life Molecular Imaging
  • Home
  • About
    • Our Mission
    • Our History
    • Our Partners
    • Compliance & Code of Conduct
  • Innovation
    • Neuroimaging
    • Cardiovascular Imaging
    • Pharma Collaborations
  • Products
    • Neuraceq®
  • Clinical Trials
    • Advance study
    • Cardiag Study
    • Expanded Access Program
  • Careers
  • News
    • Press Releases
    • Selected Publications
  • Contact
Life Molecular Imaging
  • Home
  • About
    • Our Mission
    • Our History
    • Our Partners
    • Compliance & Code of Conduct
  • Innovation
    • Neuroimaging
    • Cardiovascular Imaging
    • Pharma Collaborations
  • Products
    • Neuraceq®
  • Clinical Trials
    • Advance study
    • Cardiag Study
    • Expanded Access Program
  • Careers
  • News
    • Press Releases
    • Selected Publications
  • Contact
NEWS

Life Molecular Imaging Announces Collaboration to Provide Both its Amyloid and Tau PET Imaging Agents for Research of Alzheimer’s Disease in a Large Consortium Clinical Trial Sponsored by National Institute on Aging

23 July 2024

LEARN MORE
NEWS

Life Molecular Imaging and Jubilant Radiopharma announce Neuraceq® availability in Mobile, AL

9 July 2024

LEARN MORE
NEWS

Life Molecular Imaging Enters Agreement With Lantheus to Sub-License its Radiotheranostic Agent RM2 Targeting GRPR in Prostate and Breast Cancers

27 June 2024

LEARN MORE
NEWS

Life Molecular Imaging and SOFIE announce Neuraceq® availability in Cleveland

4 April 2024

LEARN MORE
NEWS

Life Molecular Imaging and Oryx Isotopes Industrial Company announce a Strategic Partnership for the Production and Distribution of Florbetaben (18F) in the Kingdom of Saudi Arabia and other countries in reach

6 February 2024

LEARN MORE
NEWS

Life Molecular Imaging and SOFIE announce Neuraceq® availability in Houston

9 January 2024

LEARN MORE
NEWS

CMI Inc. and Life Molecular Imaging Announce the Reimbursement of the Amyloid-PET Diagnostic Neuraceq® (florbetaben 18F) in Japan

22 November 2023

LEARN MORE
NEWS

Life Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Radiopharmaceutical Neuraceq® in China   

13 October 2023

LEARN MORE
NEWS

CMS Announces Final Decision for Coverage of Beta Amyloid PET

13 October 2023

LEARN MORE
NEWS

Life Molecular Imaging announces presentation of new scientific data at the European Association of Nuclear Medicine annual meeting 2023

5 September 2023

LEARN MORE
  • 1
  • 2
  • 3
  • 4
  • 5